A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
Study Details
Study Description
Brief Summary
The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Inducible Urticaria who remain symptomatic despite the use of H1-antihistamines.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab in patients with Chronic Inducible Urticaria (Cold Urticaria [ColdU] or Symptomatic Dermographism [SD]) who remain symptomatic despite the use of H1-antihistamines.
There is a screening period of up to 4 weeks, followed by a 20-week treatment period where patients will receive either barzolvolimab 150mg, 300mg or placebo, and then a 24-week follow up period where all patients are observed.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: barzolvolimab 150 mg in patients with Symptomatic Dermographism barzolvolimab 150 mg injection subcutaneous every 4 weeks for 20 weeks |
Biological: barzolvolimab
Subcutaneous Administration
Other Names:
|
| Experimental: barzolvolimab 300 mg in patients with Symptomatic Dermographism barzolvolimab 300 mg injection subcutaneous every 8 weeks for 20 weeks |
Biological: barzolvolimab
Subcutaneous Administration
Other Names:
|
| Placebo Comparator: Placebo Comparator in patients with Symptomatic Dermographism Placebo injection subcutaneous every 4 weeks for 20 weeks |
Drug: Matching Placebo
Subcutaneous Administration
|
| Experimental: barzolvolimab 150 mg in patients with Chronic Inducible Cold Urticaria barzolvolimab 150 mg injection subcutaneous every 4 weeks for 20 weeks |
Biological: barzolvolimab
Subcutaneous Administration
Other Names:
|
| Experimental: barzolvolimab 300 mg in patients with Chronic Inducible Cold Urticaria barzolvolimab 300 mg injection subcutaneous every 8 weeks for 20 weeks |
Biological: barzolvolimab
Subcutaneous Administration
Other Names:
|
| Placebo Comparator: Placebo Comparator in patients with Chronic Inducible Cold Urticaria Placebo injection subcutaneous every 4 weeks for 20 weeks |
Drug: Matching Placebo
Subcutaneous Administration
|
Outcome Measures
Primary Outcome Measures
- Percentage of patients with a negative provocation test at week 12 [From baseline to week 12]
Percentage of patients with a negative provocation test for Cold Inducible Urticaria [ColdU] or Symptomatic Dermographism [SD]) at week 12 For ColdU patients, a negative provocation test is defined as absence of wheals at the provocation site within 10 min at ≤ 4°C after provocation using TempTest® For SD patients, a negative provocation test is defined as absence of wheals at the provocation site within 10 min at 0 pins after provocation using the FricTest®
Secondary Outcome Measures
- Change in provocation threshold and itch for ColdU [From baseline to week 12]
Mean change from baseline to week 12 in critical temperature threshold (CTT) in patients with ColdU CTT is defined as threshold temperature at which wheals are triggered (highest temperature for cold), assessed at the 10-minute mark
- Change in provocation threshold for SD [From baseline to week 12]
Mean change from baseline to Week 12 in Critical Friction Threshold (CFT) in patients with SD CFT is the threshold pin number at which wheals are triggered, assessed at the 10-minute mark
- Change in worst itch reported after provocation for ColdU [From baseline to week 12]
Mean change in worst itch reported by numerical rating scale after provocation testing from baseline to week 12 in patients with ColdU
- Combined patients with a negative provocation test at week 12 [From baseline to week 12]
Percentage of combined patients with a negative TempTest (ColdU) or FricTest (SD) at week 12
- Change in worst itch reported after provocation for SD [From baseline to week 12]
Mean change in worst itch reported by numerical rating scale after provocation testing from baseline to week 12 in patients with SD
- Change in worst itch reported after provocation in both SD and ColdU [From baseline to week 12]
Mean change in worst itch reported by numerical rating scale after provocation testing from baseline to week 12 in patients with SD and ColdU combined
- Percentage of patients experiencing adverse events [From baseline to week 20]
Percentage of patients experiencing treatment-emergent adverse events (TEAE) examined by ColdU patients, SD patients and in combination. A TEAE is any untoward medical occurrence in a patient administered a study treatment.
Eligibility Criteria
Criteria
Key inclusion criteria:
-
Males and females, >/= 18 years of age.
-
Diagnosis of chronic ColdU or SD >/= 3 months.
-
Diagnosis of ColdU or SD despite the use of a stable regimen of second generation non-sedating H1-antihistamine as defined by:
-
Recurrent pruritic wheals with or without angioedema due to ColdU or SD for >/= 6 weeks at any time prior to Visit 1 despite the use of H1-antihistamines.
-
Must be on a stable regimen of second generation non-sedating H1-antihistamine for >/= 4 weeks prior to study treatment and agree to stay on through trial.
-
UCT < 12 during the 14 days prior to treatment.
-
Positive provocation test
-
for ColdU patients: developing a wheal at the test site within 10 min after using TempTest® at any temperature at both screening (Visit 1) and randomization (Visit
-
for SD patients: developing a wheal at the test site within 10 min after using FricTest® with ≥ 3 pins at both screening (Visit 1) and randomization (Visit 3)
-
Both males and females of child-bearing potential must agree to use highly effective contraceptives during the study and for 150 days after treatment.
-
Willing and able to complete a daily symptom electronic diary and comply with study visits.
Key exclusion criteria:
-
Women who are pregnant or nursing.
-
Active Chronic spontaneous urticaria or other forms of CIndU besides ColdU or SD that may interfere with study assessments.
-
Active, pruritic skin condition in addition to CIndU.
-
Medical condition that would cause additional risk or interfere with study procedures.
-
Known active HIV, hepatitis B or hepatitis C infection.
-
Vaccination of a live vaccine within 2 months prior to study treatment (subjects must agree to avoid vaccination during the study). Inactivated vaccines are allowed such as seasonal influenza injection or COVID-19 vaccine.
-
History of anaphylaxis
There are additional criteria that your study doctor will review with you to confirm you are eligible for the study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Clinical Research Center of Alabama | Birmingham | Alabama | United States | 35249 |
| 2 | One of a Kind Clinical Research Center, LLC | Paradise Valley | Arizona | United States | 85253 |
| 3 | Little Rock Allergy & Asthma CRC | Little Rock | Arkansas | United States | 72205 |
| 4 | Allergy & Asthma Consultants | Redwood City | California | United States | 94063 |
| 5 | Sarasota Clinical Research | Sarasota | Florida | United States | 34239 |
| 6 | Treasure Valley Medical Research | Boise | Idaho | United States | 83706 |
| 7 | Dawes Fretzin Dermatology Group, LLC - Anderson | Indianapolis | Indiana | United States | 46250 |
| 8 | Allergy & Asthma Specialists, PSC | Owensboro | Kentucky | United States | 42301 |
| 9 | Respiratory Medicine Research Institute of Michigan, PLC | Ypsilanti | Michigan | United States | 48197 |
Sponsors and Collaborators
- Celldex Therapeutics
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CDX0159-07
- 2021-006447-95